News

Medigene to participate in three international conferences

Martinsried/Munich, 28 October 2015. Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation in three upcoming conferences:

  • BIO-Europe 2015

Date: 2 - 4 November 2015
Location: Munich, Germany
Exhibitor: Booth 74
www.ebdgroup.com/bioeurope/

  • SITC 2015 Annual Meeting & Associated Programs

Date: 4 - 8 November 2015
Location: National Harbor, Maryland, USA
www.sitcancer.org/2015

  • Jefferies Global Healthcare Conference London

Date: 18 November 2015
Location: London, UK
www.jefferies.com/OurFirm/Conferences/325/248

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.

For more information, please visit www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com

To unsubscribe from the press release distribution list, please visit: www.medigene.de/unsubscribe